About Catalio

Our Portfolio

Investing in the next generation of life sciences
Scroll
[Portfolio]

Companies

We focus on life sciences companies developing next-generation drugs, devices and diagnostics, data, tools, and healthcare services and work closely with each portfolio company to build and grow the business from inception to exit.
Clear filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Affini-T
Private Equity
Co-Investments
Drugs
Private
Unrealized
US
Alentis Therapeutics
Private Equity
Drugs
Private
Unrealized
Non-Us
Anagenex
Private Equity
Drugs
Private
Unrealized
US
ArriVent
IPO in 2024
Private Equity
Drugs
Public
Realized
US
Ashvattha Therapeutics
Exit in 2019
Private Equity
Drugs
Exited
Realized
US
Atai Life Sciences
IPO in 2021
Private Equity
Co-Investments
Drugs
Public
Unrealized
Non-Us
Audicus
Loan Repayment in 2025
Structured Opportunities
Devices
Exited
Unrealized
US
Avalyn Pharma
Private Equity
Drugs
Private
Unrealized
US
AVAVA
Structured Opportunities
Devices
Private
Unrealized
US
Aviceda Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Bayesian Health
Private Equity
Diagnostics
Private
Unrealized
US
Blackrock Neurotech
Private Equity
Devices
Private
Unrealized
US
Boost Neuroscience
M&A in 2025
Private Equity
Drugs
Exited
Unrealized
US
Cage Pharmaceuticals
Private Equity
Co-Investments
Drugs
Private
Unrealized
US
Cambrian Biopharma
Private Equity
Drugs
Private
Unrealized
US
Carbon Health
Private Equity
Other
Private
Unrealized
US
Cartography
Private Equity
Drugs
Private
Unrealized
US
Celsius Therapeutics
M&A in 2024
Private Equity
Other
Exited
Realized
US
Centenara Labs (formerly Rejuveron)
Private Equity
Drugs
Private
Unrealized
Non-Us
Character Biosciences
Private Equity
Drugs
Private
Unrealized
US
Clasp Therapeutics
Private Equity
Co-Investments
Drugs
Private
Unrealized
US
Compass Pathways
IPO in 2020
Private Equity
Drugs
Public
Realized
Non-Us
Cresilon
Structured Opportunities
Devices
Private
Unrealized
US
Dianthus
IPO in 2024
Private Equity
Drugs
Public
Unrealized
US
DNA Script
Private Equity
Co-Investments
Other
Private
Unrealized
Non-Us
eGenesis
Private Equity
Drugs
Private
Unrealized
US
Elektrofi
Private Equity
Drugs
Private
Unrealized
US
eNeura
Private Equity
Devices
Private
Unrealized
US
Ensoma
Loan Repayment in 2024
Private Equity
Structured Opportunities
Drugs
Exited
Unrealized
US
Enveda
Private Equity
Drugs
Private
Unrealized
US
Erisyon
Exit in 2024
Private Equity
Other
Private
Realized
US
Faze Medicines
Private Equity
Drugs
Private
Unrealized
US
Fractyl Labs
IPO in 2024
Private Equity
Structured Opportunities
Devices
Public
Unrealized
US
Freenome
Private Equity
Co-Investments
Diagnostics
Private
Unrealized
US
Georgiamune
Private Equity
Drugs
Private
Unrealized
US
GlycoEra
Private Equity
Drugs
Private
Unrealized
Non-Us
Haystack Oncology
Exit in 2023
Private Equity
Structured Opportunities
Co-Investments
Diagnostics
Exited
Realized
US
Iambic
Private Equity
Drugs
Private
Unrealized
US
Imbria
Private Equity
Drugs
Private
Unrealized
US
Immunai
Private Equity
Other
Private
Unrealized
US
Imperative Care
Private Equity
Devices
Private
Unrealized
US
Insightec
Structured Opportunities
Co-Investments
Devices
Private
Unrealized
Non-Us
Lassen Therapeutics
Private Equity
Drugs
Private
Unrealized
US
LifeSprout, Inc.
Private Equity
Devices
Private
Unrealized
US
Metagenomi
IPO in 2024
Private Equity
Drugs
Public
Unrealized
US
MindX
Exit in 2022
Private Equity
Devices
Exited
Unrealized
US
Neumora Therapeutics
IPO in 2023
Private Equity
Drugs
Public
Realized
US
NextPoint Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Noetik
Private Equity
Other
Private
Unrealized
US
Octant Bio
Private Equity
Co-Investments
Drugs
Private
Unrealized
US
Odyssey Therapeutics
Private Equity
Drugs
Private
Unrealized
US
OnCusp Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Orasis Pharmaceuticals
Structured Opportunities
Drugs
Private
Unrealized
Non-Us
Orpheris
Exit in 2021
Private Equity
Drugs
Exited
Realized
US
Paige AI
Private Equity
Other
Private
Unrealized
US
Parabilis Medicines (formerly FogPharma)
Private Equity
Drugs
Private
Unrealized
US
Perceive Biotherapeutics
Private Equity
Drugs
Private
Unrealized
US
Perfuse Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Personal Genome Diagnostics (PGDx)
Exit in 2022
Private Equity
Diagnostics
Exited
Realized
US
Pheast Therapeutics
Private Equity
Co-Investments
Drugs
Private
Unrealized
US
Pillar Biosciences
Exit in 2024
Structured Opportunities
Diagnostics
Exited
Unrealized
US
Pink Dx
Private Equity
Diagnostics
Private
Unrealized
US
Port Therapeutics
Private Equity
Drugs
Private
Unrealized
US
PrognomiQ
Private Equity
Diagnostics
Private
Unrealized
US
Protara Therapeutics
Private Equity
Drugs
Private
Unrealized
US
ProtoAxiom
Private Equity
Other
Private
Unrealized
Non-Us
Recognify Life Sciences
Private Equity
Drugs
Private
Unrealized
US
Recursion
IPO in 2021
Private Equity
Co-Investments
Other
Public
Realized
US
RefleXion
Private Equity
Devices
Private
Unrealized
US
Resilience
Private Equity
Other
Private
Unrealized
US
Roshal Imaging
Structured Opportunities
Other
Private
Unrealized
US
Sanguine Biosciences
Structured Opportunities
Other
Private
Unrealized
US
Satellite Bio
Private Equity
Drugs
Private
Unrealized
US
Sensei Bio
IPO in 2021
Private Equity
Drugs
Public
Unrealized
US
Septerna
IPO in 2024
Private Equity
Drugs
Public
Unrealized
US
SetPoint Medical
Private Equity
Devices
Private
Unrealized
US
Sherlock Biosciences
M&A in 2025
Private Equity
Diagnostics
Exited
Unrealized
US
Sickbay
Private Equity
Structured Opportunities
Diagnostics
Private
Unrealized
US
Singular Genomics
IPO in 2021
Private Equity
Other
Public
Realized
US
Sisu Global Health
Private Equity
Devices
Private
Unrealized
US
Spiral Therapeutics
Private Equity
Drugs
Private
Unrealized
US
STAR Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Sunbird Bio
Private Equity
Diagnostics
Private
Unrealized
US
Superluminal Medicines
Private Equity
Other
Private
Unrealized
US
TapestryHealth
Structured Opportunities
Diagnostics
Private
Unrealized
US
Thrive Earlier Detection
Exit in 2020
Private Equity
Co-Investments
Diagnostics
Exited
Realized
US
Visby Medical
Structured Opportunities
Co-Investments
Devices
Private
Unrealized
US
Volastra Therapeutics
Private Equity
Drugs
Private
Unrealized
US
WindMIL Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Xilis, Inc.
Private Equity
Diagnostics
Private
Unrealized
US